Introduction

52
Raltegravir (RAL) is the first approved integrase inhibitor targeting the strand transfer 53 step of HIV integration (14) . Studies in HIV treatment-experienced as well as in naïve 54 patients have shown that RAL-containing regimens have potent antiretroviral activity Limited studies in healthy volunteers and in HIV-infected patients have shown that 79 RAL pharmacokinetics is characterised by high inter-patient variability (3,5,11,13).
80
Recently, we have shown that the pharmacokinetics of RAL in HIV-infected subjects is 81 characterised also by high intra-patient variability (4). Interestingly, in the previously 82 published studies it was shown that gender, race, age, body mass index, food intake, and 83 renal or hepatic insufficiency explain only in part the observed variability in RAL 84 pharmacokinetics (2). More recently it was also shown that the presence of allelic 85 variants in the UGT1A1 gene -that encodes for the enzyme involved in the metabolism 86 of the drug -only minimally affects plasma concentrations of RAL (1, 17) . Therefore, at 87 the present, the majority of RAL pharmacokinetic variability remains unexplained by 88 genetic and non-genetic factors.
89
In the present study we investigated whether the observed wide inter-and intra-patient were transferred into dissolution vessel by wax paper.
156
Samples were analysed for drug content using a high performance liquid Table 1 .
191
As shown in Figure 1 (Table 2) . The possibility that the pharmacokinetics of RAL could be further improved by 285 dissolving the pulverized tablets in water before taking the drug is an intriguing 286 hypothesis that needs to be investigated.
288
The use of RAL once-daily has been considered an attractive option to promote 
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